# Drug Pricing: Political Perspectives Analysis

Drug pricing raises fundamental questions about the role of government in markets, the balance between innovation incentives and affordability, the legitimacy of monopoly pricing for essential goods, and whether healthcare -- including access to medications -- is a right or a commodity. The pharmaceutical industry's argument that high prices fund innovation collides with the reality that 29% of Americans skip medications due to cost and that 125,000 die annually from medication non-adherence. Few policy issues generate such broad public consensus for reform (83% support Medicare negotiation) while remaining so resistant to legislative action.

Different political traditions offer distinct visions for how to approach drug pricing. This analysis examines the issue through nine political perspectives, exploring how each tradition approaches the core questions of market regulation, patent policy, government purchasing, and patient affordability.

---

## Perspectives Analyzed

### 1. Conservative

**Core Belief**: Free markets, limited government intervention, and strong property rights produce the most efficient allocation of resources. Government price controls distort markets and reduce innovation.

**Stance on Drug Pricing**: The current system overcharges patients partly due to government-created distortions (the patent system, FDA regulatory delays, PBM opacity), but the solution is more market competition, not government price-setting. Medicare negotiation as enacted in the IRA is an acceptable compromise for a government program, but extending price controls to commercial markets crosses a fundamental line.

**Key Priorities**:
- Increase generic and biosimilar competition through FDA regulatory streamlining
- Improve price transparency to enable market-based competition
- Reform PBMs to increase competition and reduce hidden costs
- Protect pharmaceutical patent rights as essential to innovation

**Policy Preferences**:
- Faster FDA generic and biosimilar approvals (reduce regulatory barriers)
- Price transparency requirements (list price, net price, international comparisons)
- PBM reform focused on transparency and competition (not structural mandates)
- Oppose extending Medicare negotiated prices to commercial markets
- Support limited Medicare negotiation as enacted in the IRA but oppose expansion
- Import drugs from Canada and other safe countries to increase competition

**Objections to Other Approaches**: Rejects government price-setting as a path to rationing and reduced innovation. Argues that comprehensive negotiation and international reference pricing would effectively impose foreign price controls on the U.S. market, reducing returns on pharmaceutical R&D and ultimately producing fewer new drugs.

**Engagement Consistency**: 3/5 -- Conservative positions on drug pricing are internally inconsistent. Conservatives defend pharmaceutical patents (government-granted monopolies) while opposing government price negotiation, and advocate for "free markets" in a sector where 90% of basic research is publicly funded. The tension between free-market principles and pharmaceutical industry donor interests produces variable positions depending on the specific reform proposed.

**Key Phrase**: "Competition, not government control, is the best medicine for high drug prices."

---

### 2. Liberal

**Core Belief**: Government has a responsibility to ensure that markets serve the public interest, particularly for essential goods like healthcare. Regulation is necessary to correct market failures and protect consumers.

**Stance on Drug Pricing**: The current system is fundamentally broken because it allows monopoly pricing of essential medications. The IRA was a historic first step, but comprehensive reform requires expanding negotiation to all drugs and all markets, closing patent loopholes, and ensuring no one goes without needed medications due to cost.

**Key Priorities**:
- Expand Medicare drug price negotiation to cover all high-cost drugs
- Extend negotiated prices to commercial insurance markets
- Close patent evergreening and pay-for-delay loopholes
- Cap out-of-pocket costs for all Americans, not just Medicare beneficiaries
- Ensure racial and economic equity in drug access

**Policy Preferences**:
- Comprehensive Drug Pricing Reform Act (expanded negotiation, commercial extension)
- Patent Abuse Prevention Act (end evergreening, ban pay-for-delay)
- PBM Accountability Act (transparency, rebate pass-through, divestiture)
- International reference pricing benchmarked to OECD countries
- Universal out-of-pocket caps ($2,000 annually across all markets)
- Increased NIH funding to sustain innovation independent of industry pricing

**Objections to Other Approaches**: Rejects the conservative position that market competition alone can control drug prices given the inherent monopoly power of patented drugs. Argues that incremental, competition-only reforms have failed for 40 years while patients continue to die from unaffordable medications.

**Engagement Consistency**: 4/5 -- Liberal positions are generally consistent, though tensions exist between supporting pharmaceutical innovation (which requires some pricing power) and demanding aggressive price regulation. Coalition dynamics with pharmaceutical-industry-funded patient groups occasionally complicate messaging.

**Key Phrase**: "No one should die because they can't afford their medication in the richest country on earth."

---

### 3. Progressive / Democratic Socialist

**Core Belief**: Healthcare is a human right, not a commodity. The pharmaceutical industry's profit motive is fundamentally incompatible with equitable access to essential medicines. Systemic transformation, not incremental reform, is needed.

**Stance on Drug Pricing**: The current system prioritizes shareholder returns over human life. The IRA is wholly inadequate -- it covers too few drugs, exempts commercial markets, and preserves the fundamental structure of for-profit pharmaceutical monopolies. Only comprehensive price regulation, dramatically expanded public R&D, and (ultimately) public manufacturing can solve the drug pricing crisis.

**Key Priorities**:
- Government price-setting for all prescription drugs (not just negotiation)
- Public pharmaceutical manufacturing of essential medications
- Dramatically expanded NIH funding and public-sector drug development
- Compulsory licensing for drugs developed with public funding
- Global access to essential medicines (oppose pharmaceutical IP in trade agreements)

**Policy Preferences**:
- Medicare for All with comprehensive drug coverage and government price-setting
- Government manufacturing of insulin, generics, and essential medications
- NIH funding increase to $100+ billion with public ownership of resulting patents
- Compulsory licensing under 28 U.S.C. Section 1498 for drugs whose development involved significant public funding
- Elimination of pharmaceutical advertising (direct-to-consumer and physician marketing)
- Repeal of 12-year biologic exclusivity entirely

**Objections to Other Approaches**: Views liberal reforms as insufficient half-measures that preserve the pharmaceutical industry's structural power. Argues that negotiation-based approaches still accept the legitimacy of monopoly pricing and that only public ownership of pharmaceutical development and production can truly align drug pricing with public health.

**Engagement Consistency**: 5/5 -- Progressive positions are highly consistent, flowing logically from the premise that healthcare is a right and that essential industries should serve public, not private, interests. Positions do not shift based on political dynamics.

**Key Phrase**: "Pharmaceutical companies should not profit from human suffering."

---

### 4. Libertarian

**Core Belief**: Individual liberty, free markets, and minimal government intervention produce the best outcomes. Government regulation is inherently inefficient and subject to capture by special interests.

**Stance on Drug Pricing**: High drug prices are caused primarily by government intervention -- the patent system (government-granted monopoly), FDA regulatory barriers (blocking competition), and tax policy (subsidizing employer insurance, distorting demand). The solution is to reduce government involvement, not increase it.

**Key Priorities**:
- Eliminate or dramatically shorten pharmaceutical patents
- Reduce FDA approval requirements to lower barriers to competition
- Allow unrestricted drug importation from any country
- Eliminate employer insurance tax subsidy to make patients more price-sensitive
- Oppose all government price-setting or negotiation

**Policy Preferences**:
- Reduce patent terms for pharmaceuticals to 10 years or eliminate patents entirely, replacing them with prize systems or other non-monopoly innovation incentives
- Radically streamline FDA approval (reciprocal recognition of EU/UK/Japan approvals)
- Full drug importation from any country with no government restrictions
- Eliminate the employer insurance tax exclusion (26 U.S.C. Section 106)
- Oppose Medicare negotiation, IRP, and all government price interventions
- End the 340B program and other government discount mandates

**Objections to Other Approaches**: Rejects both conservative (defend patents while opposing negotiation) and liberal/progressive (expand government power) positions as internally inconsistent or authoritarian. Argues that the pharmaceutical industry's pricing power is entirely a product of government-granted patent monopolies, and that the principled solution is to eliminate the monopoly rather than layer government price controls on top of government-created monopolies.

**Engagement Consistency**: 4/5 -- Libertarian positions are philosophically consistent (oppose both government-granted monopolies and government price controls), but the practical implication -- eliminating pharmaceutical patents -- is so politically impractical that libertarians often end up supporting incremental competition-based reforms that are indistinguishable from conservative positions.

**Key Phrase**: "Government created the problem by granting monopolies; more government is not the solution."

---

### 5. Constitutionalist

**Core Belief**: Government action must be grounded in enumerated constitutional powers. Federalism requires respecting the boundaries between federal and state authority. Property rights, including intellectual property, deserve strong protection.

**Stance on Drug Pricing**: The federal government has limited authority over drug pricing under the Commerce Clause and Spending Clause. Medicare negotiation is constitutionally permissible as a condition of voluntary program participation. Extending price controls to commercial markets raises more serious constitutional concerns. Patent rights are constitutionally protected and should not be arbitrarily curtailed.

**Key Priorities**:
- Ensure drug pricing reforms are grounded in clear constitutional authority
- Protect patent rights from retroactive government interference
- Preserve federalism by allowing states to experiment with their own approaches
- Ensure due process in any government price-setting mechanism
- Oppose compulsory licensing as a constitutional taking

**Policy Preferences**:
- Medicare negotiation within the Spending Clause framework (IRA model)
- State prescription drug affordability boards (federalism in action)
- Cautious about extending federal price mandates to commercial markets
- Oppose government manufacturing as exceeding enumerated powers
- Support patent reform through proper legislative process (not executive action)
- Require compensation if government actions substantially reduce patent value

**Objections to Other Approaches**: Opposes progressive proposals for government manufacturing and compulsory licensing as exceeding constitutional authority and violating the Takings Clause. Questions whether extending Medicare-negotiated prices to commercial markets has adequate Commerce Clause basis. Warns that concentrating pricing authority in a single federal board creates risks of arbitrary government action.

**Engagement Consistency**: 3/5 -- Constitutionalist positions on drug pricing can be inconsistent. Strict originalists may argue that the Commerce Clause does not authorize comprehensive pharmaceutical price regulation, yet they often support the patent system (Article I, Section 8) without questioning whether pharmaceutical patent terms have expanded beyond constitutional intent.

**Key Phrase**: "Reform must respect constitutional limits on federal power and protect property rights."

---

### 6. Populist

**Core Belief**: Ordinary Americans are being exploited by powerful elites and corporations. The pharmaceutical industry is a prime example of corporate greed harming working families. Reform should prioritize the interests of regular people over corporate profits.

**Stance on Drug Pricing**: Big Pharma is ripping off the American people. Drug companies charge obscene prices, spend more on buybacks than research, and deploy an army of lobbyists to block reform. Both parties have been complicit. The solution is aggressive government action to break pharmaceutical industry power and protect American families.

**Key Priorities**:
- Slash drug prices immediately and dramatically
- Hold pharmaceutical executives personally accountable for price gouging
- End pharmaceutical industry lobbying and campaign contributions
- Protect American jobs in pharmaceutical manufacturing
- Crack down on foreign countries that free-ride on American innovation

**Policy Preferences**:
- Aggressive Medicare negotiation with no limits on number of drugs or scope
- Criminal penalties for pharmaceutical executives who engage in price gouging
- Ban pharmaceutical industry campaign contributions and lobbying
- International reference pricing tied to the lowest (not median) international price
- "Buy American" requirements for government pharmaceutical purchases
- Drug importation from Canada (but skepticism of broader trade liberalization)
- Personal liability for PBM executives who engage in spread pricing

**Objections to Other Approaches**: Dismisses conservative "free market" arguments as cover for pharmaceutical industry profits. Views liberal incremental reform as insufficient and compromised by industry influence. Skeptical of libertarian proposals to weaken patents and FDA oversight, seeing them as potentially lowering drug quality.

**Engagement Consistency**: 3/5 -- Populist positions on drug pricing are emotionally consistent (against corporate greed) but can be policy-inconsistent, simultaneously demanding lower prices and more domestic manufacturing, or opposing both free trade and high domestic prices. Populist energy is episodic, surging during high-profile price controversies and receding between.

**Key Phrase**: "Big Pharma is robbing American families blind, and Washington lets them get away with it."

---

### 7. Centrist / Pragmatic

**Core Belief**: Effective policy requires evidence-based analysis, bipartisan cooperation, and practical implementation. Ideology should yield to outcomes. The best drug pricing reforms are those that can actually pass and be implemented.

**Stance on Drug Pricing**: The IRA was a breakthrough that should be built upon incrementally. Expanding negotiation, improving transparency, and accelerating competition are achievable and would produce meaningful savings. Sweeping transformation (government manufacturing, commercial price-setting) is politically unrealistic and risks unintended consequences.

**Key Priorities**:
- Expand the IRA's negotiation program to more drugs more quickly
- Bipartisan PBM transparency and reform legislation
- Patent reform to accelerate generic competition
- Evidence-based evaluation of reform impacts, including innovation effects
- Build on proven models (IRA, VA negotiation, state affordability boards)

**Policy Preferences**:
- Expand Medicare negotiation to 50+ drugs per year (phased)
- Extend insulin copay cap and OOP cap to commercial insurance (bipartisan support exists)
- PBM transparency mandates with FTC enforcement
- Patent reform targeting the most egregious abuses (pay-for-delay, patent thickets)
- Drug importation pilot programs (start with Canada, evaluate results)
- Increased NIH funding as innovation insurance
- Avoid immediate commercial market price mandates (pursue incrementally)

**Objections to Other Approaches**: Warns that progressive maximalism (government manufacturing, all-drug price-setting) will fail politically and alienate the bipartisan coalition needed for achievable reform. Also pushes back on conservative inaction, arguing that the status quo is indefensible when 29% of adults skip medications due to cost.

**Engagement Consistency**: 4/5 -- Centrist positions are highly consistent with their pragmatic framework, though the definition of "achievable" shifts with political conditions. Centrists risk being too cautious, allowing perfect to be the enemy of good, or accepting industry compromise positions that leave most of the problem unaddressed.

**Key Phrase**: "Build on what's working, fix what isn't, and make progress the American people can feel."

---

### 8. Religious Right

**Core Belief**: Policy should reflect moral principles rooted in faith. Human dignity is paramount. The vulnerable -- including the sick, the elderly, and the poor -- deserve protection. However, government should not replace individual and community responsibility.

**Stance on Drug Pricing**: It is morally wrong for Americans to die or suffer because they cannot afford medications. The pharmaceutical industry has a moral obligation to price drugs affordably, and government has a legitimate role in protecting the vulnerable from exploitation. However, government price-setting should be limited, and the private sector should remain the primary engine of innovation.

**Key Priorities**:
- Ensure drug affordability for seniors, the poor, and the chronically ill
- Uphold the moral obligation of pharmaceutical companies to act justly
- Protect faith-based healthcare organizations' access to affordable medications
- Support life-saving drug access (insulin, cancer treatments, HIV medications)
- Maintain innovation incentives for treatments that alleviate human suffering

**Policy Preferences**:
- Insulin copay caps across all insurance markets (strong support)
- Medicare negotiation for drugs treating life-threatening conditions (supported)
- Patient assistance programs funded by pharmaceutical manufacturers (moral obligation)
- Faith-based health sharing ministries should benefit from negotiated prices
- Oppose government manufacturing as government overreach
- Support 340B program for faith-based hospitals and clinics
- Cautious about international reference pricing (concerned about drug availability)

**Objections to Other Approaches**: Agrees with liberals that drug affordability is a moral imperative but disagrees on the scope of government intervention needed. Opposes progressive proposals for government manufacturing and compulsory licensing as anti-free enterprise. Uncomfortable with purely utilitarian approaches (QALYs, cost-effectiveness analysis) that may devalue the lives of the elderly or disabled.

**Engagement Consistency**: 3/5 -- Religious Right positions on drug pricing are morally consistent (protect the vulnerable) but politically variable. Alignment with conservative economic positions can create tension with the moral imperative to act aggressively on affordability. Positions may shift when pharmaceutical pricing affects constituencies (e.g., insulin pricing for rural evangelical communities).

**Key Phrase**: "It is a moral failure when our neighbors cannot afford the medications they need to live."

---

### 9. Democratic Socialist

**Core Belief**: The pharmaceutical industry exemplifies the failures of profit-driven healthcare. Medicine should be developed, manufactured, and distributed to serve human needs, not shareholder returns. Social ownership and democratic control of essential industries are necessary.

**Stance on Drug Pricing**: The drug pricing crisis is an inevitable consequence of allowing private corporations to hold monopoly power over essential medicines. Reforms that negotiate within the existing private system will always be insufficient because they preserve the fundamental profit motive that drives high prices. Only public ownership of pharmaceutical development and manufacturing can permanently solve the problem.

**Key Priorities**:
- Public pharmaceutical manufacturing of essential medications
- Government ownership of patents resulting from publicly funded research
- Elimination of pharmaceutical industry profit motive from essential medicines
- Global equity in drug access (oppose pharmaceutical IP in trade deals)
- Worker control and democratic governance of pharmaceutical enterprises

**Policy Preferences**:
- Establish a National Pharmaceutical Corporation to develop and manufacture essential drugs
- Require government patent ownership for all drugs developed with NIH funding
- Set drug prices based on production costs plus a fixed public-interest margin (not market pricing)
- Eliminate pharmaceutical direct-to-consumer advertising
- Cap pharmaceutical executive compensation
- Support Medicare for All with comprehensive drug coverage
- Abolish pharmaceutical patents (replace with prize systems for innovation)

**Objections to Other Approaches**: Argues that negotiation-based reforms accept the legitimacy of pharmaceutical profiteering. Views liberal/centrist approaches as capitulation to industry power. Rejects conservative and libertarian positions as defending corporate exploitation under the guise of market freedom.

**Engagement Consistency**: 5/5 -- Democratic socialist positions are internally consistent and ideologically stable, flowing from core principles about public ownership and democratic control. However, their political impracticality in the current U.S. context means democratic socialists often support liberal reforms as intermediate steps while maintaining their transformative vision.

**Key Phrase**: "Medicine should be a public good, not a source of private profit."

---

## Areas of Agreement

Despite their differences, several perspectives find common ground on:

- **Insulin affordability**: All nine perspectives support some form of insulin copay cap. The $35/month cap has near-universal political support, reflecting the moral power of the insulin pricing issue (a century-old drug that costs $2-$6 to manufacture selling for hundreds of dollars).
- **PBM transparency**: Conservatives, liberals, progressives, populists, centrists, and the religious right all agree that PBMs should be required to disclose their pricing practices. The degree of reform differs (transparency only vs. structural reform), but the principle of transparency is shared.
- **Patent abuse is a problem**: Even perspectives that support strong patent rights (conservative, constitutionalist) agree that pay-for-delay settlements and patent evergreening represent abuse of the system. The disagreement is over the scope of reform, not whether reform is needed.
- **Faster generic competition**: All perspectives support faster entry of generic drugs, though they differ on whether the pathway is regulatory streamlining (conservative, libertarian), patent reform (liberal, progressive), or both.

---

## Fundamental Disagreements

Irreconcilable differences that reflect core value conflicts:

- **Government price-setting vs. market pricing**: Progressives and democratic socialists view government price-setting as essential and morally necessary; conservatives and libertarians view it as an unconstitutional and economically destructive intrusion. This reflects a fundamental disagreement about whether prescription drugs are commodities that should be priced by markets or public goods that require government control. Compromise proposals (negotiation, reference pricing) attempt to bridge this divide but satisfy neither extreme.
- **Public vs. private pharmaceutical development**: Democratic socialists and some progressives advocate for public pharmaceutical manufacturing and government patent ownership. Conservatives, libertarians, and centrists view this as government overreach that would reduce innovation. This disagreement reflects deeper ideological differences about the role of the private sector in essential industries.
- **Innovation vs. affordability weighting**: All perspectives acknowledge the tension between innovation incentives and drug affordability, but they weight these values differently. Conservatives and libertarians prioritize innovation (arguing that future patients benefit from new drugs); progressives and democratic socialists prioritize affordability (arguing that today's patients are dying from unaffordable medications). This is a genuine values conflict, not merely an empirical disagreement.

---

## Potential Compromises

Policy approaches that might bridge some divides:

- **Expanded negotiation with innovation safeguards**: Expand Medicare negotiation to cover more drugs (liberal/centrist priority) while pairing it with increased NIH funding and extended exclusivity for genuinely novel first-in-class drugs (conservative/industry concern). This trades broader price regulation for stronger innovation incentives and could attract bipartisan support.
- **PBM structural reform with competition focus**: Require PBM transparency and rebate pass-through (broad agreement) while framing divestiture as a competition-enhancing measure (conservative/libertarian principle) rather than government structural mandate. This reframes PBM reform in market-competition terms rather than regulatory terms.
- **Value-based pricing instead of price caps**: Instead of setting arbitrary price caps, establish a Drug Value Assessment Board that evaluates each drug's therapeutic benefit relative to alternatives and sets prices proportional to demonstrated value. This satisfies the liberal demand for price regulation, the conservative demand for market-based principles, and the centrist demand for evidence-based policy. The UK's NICE model demonstrates this approach can work.
- **Patent reform as market competition**: Frame patent reform (ending evergreening, banning pay-for-delay) as a pro-competition measure rather than an anti-industry measure. Conservative and libertarian support for competition can be aligned with liberal and progressive support for generic access. Patent reform has the broadest potential coalition of any drug pricing reform.
- **Drug importation as consumer choice**: Frame importation as empowering consumers to choose where they purchase medications (libertarian and conservative principle) rather than as government price regulation. The safety framework can be designed to satisfy both regulatory and market-oriented constituencies.

---

## Summary: Engagement Consistency Distribution

| Perspective | Engagement Consistency | Notes |
|---|---|---|
| Conservative | 3/5 | Defends government-granted monopolies (patents) while opposing government negotiation; influenced by donor interests |
| Liberal | 4/5 | Generally consistent; occasional tension between innovation support and aggressive regulation |
| Progressive | 5/5 | Highly consistent; positions flow logically from healthcare-as-right premise |
| Libertarian | 4/5 | Philosophically consistent but practically constrained; often defaults to conservative positions |
| Constitutionalist | 3/5 | Selective application of constitutional principles; supports patent system but questions regulation |
| Populist | 3/5 | Emotionally consistent but policy-inconsistent; episodic engagement |
| Centrist | 4/5 | Consistent pragmatism; risk of excessive caution |
| Religious Right | 3/5 | Morally consistent but politically variable; donor and coalition pressures create contradictions |
| Democratic Socialist | 5/5 | Highly consistent; limited by political impracticality of core positions |

---

## Master Comparison Table

| Dimension | Conservative | Liberal | Progressive | Libertarian | Constitutionalist | Populist | Centrist | Religious Right | Dem. Socialist |
|---|---|---|---|---|---|---|---|---|---|
| Medicare negotiation expansion | Cautious | Strong support | Support (insufficient) | Oppose | Support (limited) | Strong support | Support (phased) | Support | Support (insufficient) |
| Commercial market extension | Oppose | Strong support | Support | Oppose | Cautious | Support | Cautious | Cautious | Support |
| International reference pricing | Cautious | Support | Support | Mixed | Cautious | Support (lowest price) | Support (phased) | Cautious | Support |
| Patent reform | Support (limited) | Strong support | Strong support | Radical reform | Support (cautious) | Support | Support | Support (limited) | Abolish patents |
| PBM transparency | Support | Strong support | Support | Support | Support | Strong support | Strong support | Support | Support |
| PBM divestiture | Cautious | Support | Strong support | Oppose mandate | Cautious | Support | Cautious | Cautious | Support |
| Drug importation | Support | Support | Support | Strong support | Support | Support (from Canada) | Support (pilot) | Cautious | Support |
| Government manufacturing | Oppose | Cautious | Strong support | Oppose | Oppose | Mixed | Oppose | Oppose | Strong support |
| OOP caps (all markets) | Cautious | Strong support | Support | Oppose mandates | Cautious | Support | Support | Support | Support |
| Increased NIH funding | Support | Strong support | Strong support | Cautious | Cautious | Mixed | Strong support | Support | Strong support |

---

## Solution Support Matrix

| Solution | Likely Support | Likely Opposition | Swing Votes |
|---|---|---|---|
| Insulin copay cap extension | All 9 perspectives | None | N/A (near-universal support) |
| PBM transparency requirements | Conservative, Liberal, Progressive, Populist, Centrist, Religious Right, Constitutionalist | None significant | Libertarian (case-by-case) |
| Expanded Medicare negotiation (50+ drugs) | Liberal, Progressive, Populist, Centrist, Dem. Socialist | Libertarian | Conservative, Constitutionalist, Religious Right |
| Patent reform (end evergreening/pay-for-delay) | Liberal, Progressive, Libertarian, Populist, Centrist, Dem. Socialist | None significant | Conservative, Constitutionalist, Religious Right |
| Commercial market price extension | Liberal, Progressive, Populist, Dem. Socialist | Conservative, Libertarian | Centrist, Constitutionalist, Religious Right |
| PBM divestiture mandate | Liberal, Progressive, Populist, Dem. Socialist | Libertarian | Conservative, Centrist, Constitutionalist, Religious Right |
| International reference pricing | Liberal, Progressive, Populist, Dem. Socialist | Libertarian (oppose gov. mechanism) | Conservative, Centrist, Constitutionalist, Religious Right |
| Government pharmaceutical manufacturing | Progressive, Dem. Socialist | Conservative, Libertarian, Constitutionalist, Religious Right | Liberal, Centrist, Populist |

---

## Document Navigation

- Up: [Drug Policy](../01-overview.md)
- Previous: [Legislation](11-legislation.md)
